The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04106219
Recruitment Status : Active, not recruiting
First Posted : September 26, 2019
Last Update Posted : March 25, 2024
New Approaches to Neuroblastoma Therapy Consortium (NANT)
Innovative Therapies for Children with Cancer in Europe (ITCC)
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : April 13, 2022
Estimated Study Completion Date : August 25, 2024